Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Health Canada issues Screening Acceptance Letter in connection with NexMed's NDS for Vitaros

NexMed, Inc., a specialty CRO with a pipeline of product candidates based on the NexACT technology, today announced that Health Canada has confirmed acceptance of the Company's CMC response for review. The Screening Acceptance Letter from Health Canada was issued in connection with its New Drug Submission for Vitaros, the Company's topical treatment for erectile dysfunction.

24 Jun 2010

BioSante closes $15 million registered direct offering

BioSante Pharmaceuticals, Inc. today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante received net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.

24 Jun 2010

Nymox reports positive new results from NX02-0014 follow-up study of NX-1207 for BPH

Nymox Pharmaceutical Corporation is pleased to report positive new results from the 48-60 month follow-up study of patients treated with NX-1207 in Study NX02-0014. The initial study, completed in the U.S. in 2006, reached statistical significance in Intent-to-Treat Primary Efficacy outcomes at 90 days post-treatment with NX-1207 2.5 mg.

23 Jun 2010

FDA Advisory Committee recommendation against flibanserin will not affect LibiGel program: BioSante

BioSante Pharmaceuticals, Inc. commented today that the recommendation on June 18, 2010 by the FDA Advisory Committee regarding the safety and efficacy of flibanserin (Boehringer-Ingelheim) will have no impact on its own ongoing development program or approval pathway for LibiGel (testosterone gel), for the treatment of hypoactive sexual desire disorder (HSDD).

22 Jun 2010

Independent DMC recommends continuation of BioSante's ongoing LibiGel CV and Breast Cancer Safety Study

BioSante Pharmaceuticals, Inc., today announced that the independent Data Monitoring Committee (DMC) of the ongoing LibiGel® Cardiovascular (CV) and Breast Cancer Safety Study unanimously recommended study continuation without modifications, after its third review of the study's unblinded safety data. The review was based on data from almost 1,500 women-years of exposure.

21 Jun 2010

BioSante announces $15 million registered direct offering

BioSante Pharmaceuticals, Inc. today announced that it has received commitments from several institutional investors to purchase $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante expects to receive net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.

21 Jun 2010

BioSante announces presentation of LibiGel safety update at ENDO 2010

BioSante Pharmaceuticals, Inc., will present a LibiGel safety update at the 2010 Annual Meeting of the Endocrine Society (ENDO), being held from June 19-22, 2010 in San Diego, California.

18 Jun 2010

Obesity linked to bad sexual health: French Study

Now French researchers have found a link between obesity and bad sexual health in their study of 12,364 men and women aged 18 to 69 ranging from normal weight to obese who lived in France in 2006.

17 Jun 2010

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced results from a pre-clinical study showing that calcipotriene 0.005% and betamethasone dipropionate 0.064%, when formulated with NexACT®, results in a topical treatment which shows bioequivalecy in efficacy to Talconex®, one of the leading topical treatments marketed for patients with mild to moderate psoriasis.

16 Jun 2010

Nymox near completion of new NX-1207 follow-up study for BPH

Nymox Pharmaceutical Corporation announced today that the Company is nearing completion of a new multi-center U.S. long-term follow-up study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH). Nymox expects to report final results and statistical analysis for the study in the next 1-2 weeks. The new study concerns assessment of the 48-60 month efficacy and benefits of a single treatment of NX-1207.

16 Jun 2010

NexMed provides update on Vitaros NDS with Health Canada

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today provided an update on the status of its New Drug Submission ("NDS") with Health Canada for Vitaros®, the Company's topical treatment for erectile dysfunction.

11 Jun 2010

Therapies for female sexual dysfunction

Many women experience problems in the bedroom at one time or another. Female sexual dysfunction is not uncommon and although some women and healthcare providers have difficulty discussing it, it has been recognized by the medical community for decades. In fact, for the last twenty years, it has been listed in the Diagnostic and Statistical Manual of Mental Disorders, a manual published by the American Psychiatric Association, used to classify and diagnose psychological disorders.

10 Jun 2010

GE Global Research awarded $4M grant to optimize new nerve labeling agent and imaging system

Researchers from GE Global Research announced today that they have been awarded a four-year, $4 million grant from the National Institutes of Health, to optimize a new nerve labeling agent and imaging system. In the future, this agent could help surgeons see delicate nerve endings that are prone to damage during certain procedures, such as prostate surgery.

10 Jun 2010

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

BioSante Pharmaceuticals, Inc. today announced the receipt of Orphan Drug designation for GVAX CML Vaccine in the treatment of chronic myeloid leukemia (CML) from the FDA's Office of Orphan Products Development. Orphan drug designation, as granted by the U.S. Orphan Drug Act, is for a product to treat a rare disease or condition that affects fewer than 200,000 people in the U.S. Orphan drug designation qualifies the sponsor of the product for tax credits and seven years of marketing exclusivity, among other benefits.

7 Jun 2010

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

3 Jun 2010

Protox Therapeutics reports positive data from Phase 2b study of PRX302 in BPH

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive six month data from its double-blind placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH) a bothersome urologic condition that affects the quality of life of more than 50 million men worldwide.

2 Jun 2010

Shionogi Pharma presents study results of PSD502 for treatment of primary PE at AUA 2010

Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., today presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray being developed for the treatment of primary premature ejaculation. These data were presented at the 2010 American Urological Association Annual Meeting in San Francisco.

2 Jun 2010

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that two oral podium presentations on the company's lead candidate, PRX302, will be made at the 2010 Annual Meeting of the American Urological Association (AUA). These presentations will include six month data from the Phase 2b clinical study of PRX302 called TRIUMPH, in patients with moderate to severe benign prostatic hyperplasia (BPH).

1 Jun 2010

Shionogi Pharma presents data on PSD502 pivotal studies for primary premature ejaculation at 2010 AUA

Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., today presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray being developed for the treatment of primary premature ejaculation (PE). These data were presented at the 2010 American Urological Association (AUA) Annual Meeting in San Francisco.

1 Jun 2010

Study measures effects of BPA on male reproductive system

Increasing Bisphenol-A levels in urine are associated with worsening male sexual function, according to a Kaiser Permanente study appearing online in the Journal of Andrology.

28 May 2010

Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Health Canada issues Screening Acceptance Letter in connection with NexMed's NDS for Vitaros

BioSante closes $15 million registered direct offering

Nymox reports positive new results from NX02-0014 follow-up study of NX-1207 for BPH

FDA Advisory Committee recommendation against flibanserin will not affect LibiGel program: BioSante

Independent DMC recommends continuation of BioSante's ongoing LibiGel CV and Breast Cancer Safety Study

BioSante announces $15 million registered direct offering

BioSante announces presentation of LibiGel safety update at ENDO 2010

Obesity linked to bad sexual health: French Study

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

Nymox near completion of new NX-1207 follow-up study for BPH

NexMed provides update on Vitaros NDS with Health Canada

Therapies for female sexual dysfunction

GE Global Research awarded $4M grant to optimize new nerve labeling agent and imaging system

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

Protox Therapeutics reports positive data from Phase 2b study of PRX302 in BPH

Shionogi Pharma presents study results of PSD502 for treatment of primary PE at AUA 2010

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Shionogi Pharma presents data on PSD502 pivotal studies for primary premature ejaculation at 2010 AUA

Study measures effects of BPA on male reproductive system

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in